Abstract

The purpose of this program project grant is to investigate the immunobiology and improve the therapeutic effects of syngeneic, autologous, and allogeneic marrow transplantation in clinical malignancy and in disease involving bone marrow failure. The proposal is made up of five projects: (1) Therapeutic Application of Marrow Transplantation and Supportive Program Services; (2) Immunogenetics as Applied to Clinical Bone Marrow Transplantation; (3) Graft-Versus-Host Reaction and Disease (GVHD); (4) Autologous Lympho-hematopoietic Transplantation and (5) Radiotherapy as Applied to Lympho-hematopoietic Transplantation. The objectives of the various projects are: (1) Explore the therapeutic potential of cytoreductive treatment combined with syngeneic, autologous, and allogeneic marrow transplantation in human malignancy and aplastic anemia; (2) identify and characterize non-HLA and HLA-linked factors that are pertinent to engraftment and GVHD; (3) examine in depth the nature, prediction, prevention and treatment of GVHD; (4) further develop the methodology and study the effects of autologous lympho-hematopoietic transplantation in malignancy; and (5) study the effects of fractionated radiotherapy together with chemotherapy in preclinical models.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA015396-15
Application #
3092663
Study Section
Clinical Cancer Program Project Review Committee (CCP)
Project Start
1976-09-30
Project End
1988-11-30
Budget Start
1987-02-01
Budget End
1988-11-30
Support Year
15
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811
Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224
Ghosh, Nilanjan; Ye, Xiaobu; Tsai, Hua-Ling et al. (2017) Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant 23:1903-1909
Majzner, Robbie G; Mogri, Huzefa; Varadhan, Ravi et al. (2017) Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant 23:612-617
Alonso, Salvador; Jones, Richard J; Ghiaur, Gabriel (2017) Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol 54:17-25
Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280
Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400
Kanakry, Christopher G; Bolaños-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393

Showing the most recent 10 out of 456 publications